In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis
Science Advances · 2026
DOI: 10.1126/sciadv.aeh6590 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, 2026. Verfasst von Hong Xiao und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Ultrasound, Laboratory of Novel Optoacoustic (Ultrasonic) Imaging, The Third Affiliated Hospital of Sun Yat-sen University, Gua…. Hauptthemen laut MEDLINE: Liver Cirrhosis, Liposomes, RNA, Messenger, Macrophages. Die Arbeit nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Basic and Applied Basic Research Foundation of Guangdong Province, the fifth Five-Year Project of the Third Affiliated Hospital of Sun Yat-Sen University.
Abstract (Originalsprache)
Liver fibrosis is a severe complication of diverse chronic liver diseases characterized by a dysregulated hepatic microenvironment, and effective clinical therapeutic strategies for this condition remain lacking to date. Chimeric antigen receptor macrophages (CAR-Ms) hold considerable therapeutic potential for liver fibrosis via antigen-specific recognition and efferocytotic activity, yet their clinical translation is largely hindered by the sophisticated ex vivo preparation procedures. Herein, we report an in situ CAR-M engineering strategy that uses a phosphatidylserine (PS)–incorporated, macrophage-targeted lipid nanoparticle (LNP) for the codelivery of CAR messenger RNA (mRNA) and Cas9 mRNA in vivo. Our findings demonstrate that this engineered LNP achieves efficient targeting of liver-resident macrophages. Transfection with fibroblast activation protein α (FAPα)–CAR mRNA equips macrophages with the capacity to specifically target activated hepatic stellate cells (aHSCs), whereas Cas9-mediated follistatin-like protein 1 (FSTL-1) gene editing enhances the efferocytotic function of macrophages in liver tissues. Consequently, functional CAR-Ms are generated in situ, which elicits robust antifibrotic effects, including reduced collagen deposition, restored sinusoidal architecture and enhanced immune-mediated antifibrotic activity. Collectively, our customized LNP-mediated in situ engineering of liver macrophages into CAR-Ms enables precise antifibrotic intervention for liver fibrosis and circumvents the cumbersome ex vivo CAR-M preparation process.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Ultrasound, Laboratory of Novel Optoacoustic (Ultrasonic) Imaging, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- Nanomedicine Research Center, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- PCFM Lab of Ministry of Education, School of Materials Science and Engineering, Sun Yat-sen University, Guangzhou 510275, China.
ORCID-Profile: Hong Xiao, Xiaoxia Li, Xiaoyan Miao, Tinghui Yin, Xintao Shuai, Jie Ren
Förderung
- National Natural Science Foundation of China
- Basic and Applied Basic Research Foundation of Guangdong Province
- the fifth Five-Year Project of the Third Affiliated Hospital of Sun Yat-Sen University
- the Municipal Schools (Institutes) Joint Funding Project Basic Research Programme encompasses the Municipal Key Laboratory Construction Project
- Hong Xiao the China International Medical Foundation
Zitieren
APA
Xiao, H., Li, X., Cai, K., Leng, Y., Miao, X., Yin, T., Shuai, X., & Ren, J. (2026). In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis. Science Advances. https://doi.org/10.1126/sciadv.aeh6590
Vancouver
Xiao H, Li X, Cai K, Leng Y, Miao X, Yin T, et al. In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis. Science Advances. 2026. doi:10.1126/sciadv.aeh6590
BibTeX
@article{Xiao2026,
author = {Xiao, Hong and Li, Xiaoxia and Cai, Kaimin and Leng, Yifei and Miao, Xiaoyan and Yin, Tinghui and Shuai, Xintao and Ren, Jie},
title = {In situ CAR-M engineered by liposomal mRNA nanomedicine remodels fibrotic microenvironment for ameliorating liver fibrosis},
journal = {Science Advances},
year = {2026},
doi = {10.1126/sciadv.aeh6590}
}
EUVIMED